An integrated genomic analysis of human glioblastoma multiforme by Parsons D Williams, Jones Sin, Zhang Xiaosong, Lin Jimmy Cheng-Ho, Leary Rebecca J, Angenendt Philipp, Mankoo Parminder, Carter Hannah, Siu I-Mei, Gallia Gary L, Olivi Alessandro, McLendon Roger, Rasheed B Ahmed, Keir Stephen, Nikolskaya Tatiana, Nikolsky Yuri, Busam Dana A, Tekleab Hanna, Diaz Luis A, Hartigan James, Smith Doug R, Strausberg Robert L, Marie Suely Kazue Nagahashi, Shinjo Sueli Mieko Oba, Yan Hai, Riggins Gregory J, Bigner Darell D, Karchin Rachel, Papadopoulos Nick, Parmigiani Giovanni, Vogelstein Bert, Velculescu Victor E, Kinzler Kenneth W in Science (New York, N.Y.) (2008).

[PMID: 18772396] PubMed


Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.